Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial-Reference-Cited by-同舟云学术

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial

Published:2012-05 Issue:5 Volume:23 Page:1185-1189
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Gladieff L.,Ferrero A.,De Rauglaudre G.,Brown C.,Vasey P.,Reinthaller A.,Pujade-Lauraine E.,Reed N.,Lorusso D.,Siena S.,Helland H.,Elit L.,Mahner S.

Funder

Merck, formerly Schering-Plough Corp

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/5/1185/13785991/mdr441.pdf

Reference18 articles.

1. Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study;Pujade-Lauraine;Proc Am Soc Clin Oncol,2002

2. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials;Blackledge;Br J Cancer,1989

3. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan;Gordon;J Clin Oncol,2001

4. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer;Gordon;Gynecol Oncol,2004

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-02

2. Epithelial Ovarian Cancer;Tata Memorial Centre Textbook of Oncology;2024

3. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-07-05

4. Epithelial Ovarian Cancer: A Five Year Review;Medicina;2023-06-21

5. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line;British Journal of Cancer;2023-02-09